Gritstone Bio Q1 2024 GAAP EPS $(0.34) Misses $(0.31) Estimate, Sales $1.742M Beat $1.104M Estimate
Gritstone Bio Q1 2024 GAAP EPS $(0.34) Misses $(0.31) Estimate, Sales $1.742M Beat $1.104M Estimate
Gritstone Bio 2024年第一季度公認會計准則每股收益美元(0.34)未達到預期(0.31)美元,銷售額17.42萬美元超過11.04萬美元的預期
Gritstone Bio (NASDAQ:GRTS) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.31) by 9.68 percent. This is a 13.33 percent decrease over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $1.742 million which beat the analyst consensus estimate of $1.104 million by 57.77 percent. This is a 28.69 percent decrease over sales of $2.443 million the same period last year.
Gritstone Bio(納斯達克股票代碼:GRTS)公佈的季度虧損爲每股0.34美元,比分析師普遍預期的0.31美元(0.31美元)低9.68%。這比去年同期每股虧損0.30美元(0.30美元)下降了13.33%。該公司公佈的季度銷售額爲17.42萬美元,比分析師普遍預期的11.4萬美元高出57.77%。這比去年同期的244.3萬美元銷售額下降了28.69%。